Biological Activity of Copper(II) Complex (2-((2-(Prop-2-En-1-Ylcarbamothioyl)Hydrazinylidene)Methyl)Phenolato)-Chloro-Copper(II) Monohydrate

Author(s): Olga Garbuz, Vasilii Graur, Ianina Graur, Nadejda Railean, Ion Toderas, Elena Pahontu, Ilie Ceban, Viorel Jinga, Dorin Istrati, Emil Ceban, Aurelian Gulea

The ligand 2-(2-hydroxybenzylidene)-N-(prop-2-en-1-yl)hydrazinecarbothioamide (H2L) and its copper(II) coordination compound (2-((2-(prop-2-en-1-ylcarbamothioyl)hydrazinylidene)methyl)phenolato)-chloro-copper(II) monohydrate [Cu(HL)Cl]•H2O were synthesized. The antiproliferative activity of the tested compounds was assessed in vitro using RD (human muscle rhabdomyosarcoma spindle and large multinucleated cells), HeLa (human cervix adenocarcinoma cells), BxPC-3 (human pancreatic adenoma cells) and MDCK (Madin-Darby canine kidney epithelial normal cells) cell lines, and their selectivity indexes (SIs). The tested complex exhibited superior anticancer activity compared to Doxorubicin (DOXO), with lower IC50 values against cancer cells and SIs exceeding those of DOXO. The tested compounds demonstrated high antioxidant effects against ABTS•+ radical cation. Furthermore, the toxicity of the compounds was investigated in vivo using Daphnia magna through bioassay and microanalysis. The results suggest that the tested copper complex has potential as an effective anticancer therapy candidate.

© 2016-2024, Copyrights Fortune Journals. All Rights Reserved